Serena Williams Opens Up on GLP-1 Weight-Loss Journey, Joins Ro as Ambassador

NEW YORK, Aug. 21, 2025 – Serena Williams, the 23-time Grand Slam champion and former world No. 1, spoke out today about her use of GLP-1 medications. She shared that these treatments helped her drop 31 pounds after welcoming her two daughters. On NBC’s “Today” show, Williams said choosing GLP-1 therapy was key. It helped her break through postpartum weight-loss plateaus, which stuck around even with hard training and diet changes.

Williams, 43, shared that after retiring from professional tennis in 2022 and having her second daughter in 2023, “no amount of running, walking, or professional-level training” helped her meet her health goals. Reflecting on her journey, she said, “I trained hard, ate well, and pushed myself. But after having kids, my body just wouldn’t respond.”

Telehealth firm Ro announced that Williams will be a celebrity patient ambassador for its weight-loss program. He will lead a national campaign to normalize the clinical use of GLP-1 receptor agonists. This effort aims to reduce the stigma around their role in weight management. Williams will appear on digital, broadcast, and out-of-home platforms. She will share her story and encourage others to seek support for their health journeys.

““My body needed the GLP-1 and clinical support,” Williams told “Today.” ““This isn’t a shortcut. It’s healthcare.” She stressed that the medications helped reduce weight and eased knee pain from pregnancy and intense exercise. Williams hopes her honesty will lead to more open talks about how biology affects weight. She also wants to highlight that medication can be a key part of a complete health plan.

Ro CEO Zachariah Reitano praised Williams for speaking openly about her health. He said, “By sharing her story, Serena is helping millions who feel ashamed to seek support for weight loss.” The campaign builds on Ro’s earlier work with basketball star Charles Barkley. It aims to make GLP-1 treatments more accessible across the country.

Williams announced this news as public interest in GLP-1 therapies grows. These drugs were first made for diabetes but have shown great success in helping with weight loss. They work by mimicking a gut hormone that reduces appetite. More high-profile figures are sharing their stories. Because of this, industry watchers expect greater demand for GLP-1 medications. They see these drugs becoming a key part of preventive health care.